# CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

> **NCT06465537** · NA · RECRUITING · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma

## Interventions

- **GENETIC:** BD113vVLP

## Key facts

- **NCT ID:** NCT06465537
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465537, "CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06465537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*